Discover
CLDI
Calidi Biotherapeutics, Inc.
0.16
100 x 0.15
1200 x 0.15
bid
ask
-
0.01
7.06%
650 @ 07:10 AM
0.16 -0.00 (1.65%)
| Ytd | -86.50% | |
| 1y | -94.28% |
0.15
day range
0.16
0.12
52 week range
19.20
| Open | 0.16 | Prev Close | 0.17 | Low | 0.15 | High | 0.16 | Mkt Cap | 3.05M |
| Vol | 2.75M | Avg Vol | 5.98M | EPS | -4.17 | P/E | N/A | Forward P/E | -1.57 |
| Beta | 0.57 | Short Ratio | 0.88 | Inst. Own | 2.71% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.19 | 200-d Avg | 0.86 | 1yr Est | 6.25 |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-06-27 | Ladenburg Thalmann | Upgrade | Buy | |
| 2024-05-15 | Baird | Upgrade | Outperform | Outperform |
| 2024-03-21 | Baird | Upgrade | Outperform | Outperform |
| 2024-03-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-11-22 | HC Wainwright & Co. | Upgrade | Buy | |
| 2023-10-09 | Baird | Upgrade | Outperform |
Profile
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-12-16 | CAMAISA ALLAN | Chief Executive Officer | 66.71K | Sale |
| 2023-09-11 | FIRST LIGHT ACQUISITION GROUP LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
| 2024-06-27 | LEFTWICH SCOTT | Director | 560.87K | Stock Award(Grant) |
| 2024-06-27 | SCHOENECK JAMES A | Director | 1.07M | Stock Award(Grant) |
| 2024-06-27 | STEWART ALAN R | Director | 154.09K | Stock Award(Grant) |
| 2023-12-20 | VECCHIOLLA THOMAS A | Director | 365.11K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Cable Car Capital LLC | 82.94K | 116.94K | 0.40% |
| 2024-09-29 | CPR Investments Inc. | 56.00K | 78.96K | 0.27% |
| 2024-09-29 | Red Wave Investments, LLC | 46.46K | 65.51K | 0.23% |
| 2024-09-29 | Geode Capital Management, LLC | 39.61K | 55.85K | 0.19% |
| 2024-09-29 | Susquehanna International Group, LLP | 23.54K | 33.20K | 0.11% |
| 2024-09-29 | Delta Investment Management, LLC | 21.02K | 29.64K | 0.10% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 31.17K | 43.94K | 0.15% |
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 10.00K | 14.10K | 0.05% |
| 2024-10-30 | Fidelity Total Market Index Fund | 10.17K | 14.34K | 0.05% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 7.45K | 10.50K | 0.04% |
| 2024-08-30 | Brinker Capital Destinations Tr-Destinations Multi Strategy Alt Fd | 7.03K | 9.92K | 0.03% |
| 2024-09-29 | Driehaus Event Driven Fund | 2.44K | 3.43K | 0.01% |
Split
| Split | Date |
|---|---|
| 1 : 12 | 2025-08-05 |
| 1 : 10 | 2024-07-15 |